MedTrace Logo

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

NCT00031863 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-08-02

No results posted yet for this study

Summary

RATIONALE: Rofecoxib may stop the growth of cancer by stopping blood flow to the tumor and killing tumor cells that remain after surgery. It is not yet known if rofecoxib is effective in treating colorectal cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of giving rofecoxib after surgery in treating patients who have stage II or stage III colorectal cancer.

Conditions

Interventions

DRUG

rofecoxib

PROCEDURE

adjuvant therapy

Sponsors & Collaborators

  • Cancer Research Campaign Clinical Trials Centre

    lead OTHER

Principal Investigators

  • David J. Kerr, MD, FRCP, DSc · Oxford University Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Completion
2007-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031863 on ClinicalTrials.gov